Mark Lown

2.3k total citations
46 papers, 870 citations indexed

About

Mark Lown is a scholar working on Cardiology and Cardiovascular Medicine, Geriatrics and Gerontology and Economics and Econometrics. According to data from OpenAlex, Mark Lown has authored 46 papers receiving a total of 870 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Cardiology and Cardiovascular Medicine, 10 papers in Geriatrics and Gerontology and 10 papers in Economics and Econometrics. Recurrent topics in Mark Lown's work include Blood Pressure and Hypertension Studies (11 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and Pharmaceutical Practices and Patient Outcomes (9 papers). Mark Lown is often cited by papers focused on Blood Pressure and Hypertension Studies (11 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and Pharmaceutical Practices and Patient Outcomes (9 papers). Mark Lown collaborates with scholars based in United Kingdom, United States and Qatar. Mark Lown's co-authors include Paul Little, Beth Stuart, George Lewith, Michael Moore, Arthur Yue, E. Swidenbank, B.W. Hogg, Merlin Willcox, Richard Hobbs and James P Sheppard and has published in prestigious journals such as JAMA, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Mark Lown

43 papers receiving 846 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Lown United Kingdom	17	338	141	99	93	79	46	870
Katy E. Trinkley United States	17	311 0.9×	168 1.2×	83 0.8×	54 0.6×	193 2.4×	68	1.0k
Hong Ji Song South Korea	20	162 0.5×	103 0.7×	55 0.6×	125 1.3×	48 0.6×	74	1.3k
Aaron M Tejani Canada	16	254 0.8×	63 0.4×	52 0.5×	198 2.1×	52 0.7×	54	922
Nina J. Weidle United States	8	140 0.4×	241 1.7×	74 0.7×	91 1.0×	64 0.8×	14	951
Eyob Alemayehu Gebreyohannes Ethiopia	18	461 1.4×	206 1.5×	131 1.3×	231 2.5×	115 1.5×	56	1.1k
Chuenjid Kongkaew Thailand	19	201 0.6×	543 3.9×	177 1.8×	130 1.4×	73 0.9×	39	1.8k
Hiroki Satoh Japan	19	213 0.6×	86 0.6×	27 0.3×	86 0.9×	53 0.7×	95	1.4k
Dan Perri Canada	17	163 0.5×	42 0.3×	135 1.4×	172 1.8×	52 0.7×	36	1.3k
Chi‐Chuan Wang Taiwan	16	118 0.3×	59 0.4×	55 0.6×	143 1.5×	39 0.5×	73	821
Raghupathy Anchala India	14	414 1.2×	32 0.2×	86 0.9×	94 1.0×	145 1.8×	26	893

Countries citing papers authored by Mark Lown

Since Specialization

Citations

This map shows the geographic impact of Mark Lown's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Lown with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Lown more than expected).

Fields of papers citing papers by Mark Lown

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Lown. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Lown. The network helps show where Mark Lown may publish in the future.

Co-authorship network of co-authors of Mark Lown

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Lown. A scholar is included among the top collaborators of Mark Lown based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Lown. Mark Lown is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Radcliffe, Eloise, Alejandra Recio‐Saucedo, Clare Howard, et al.. (2025). Development of a complex multidisciplinary medication review and deprescribing intervention in primary care for older people living with frailty and polypharmacy. PLoS ONE. 20(4). e0319615–e0319615. 4 indexed citations

Sheppard, James P, Eleanor Temple, Ariel Wang, et al.. (2024). Effect of antihypertensive deprescribing on hospitalisation and mortality: long-term follow-up of the OPTiMISE randomised controlled trial. The Lancet Healthy Longevity. 5(8). e563–e573. 6 indexed citations

Lown, Mark, Kirsten A. Smith, Ingrid Müller, et al.. (2023). Internet Tool to Support Self-Assessment and Self-Swabbing of Sore Throat: Development and Feasibility Study. Journal of Medical Internet Research. 25. e39791–e39791. 4 indexed citations

Wilcox, Christopher R, Ingrid Müller, Abigail Moore, et al.. (2023). Feasibility of a placebo-controlled trial of antibiotics for possible urinary tract infection in care homes: a qualitative interview study. BJGP Open. 7(3). BJGPO.2023.0014–BJGPO.2023.0014.

Francis, Nick, Taeko Becque, Merlin Willcox, et al.. (2023). Non-pharmaceutical interventions and risk of COVID-19 infection: survey of U.K. public from November 2020 – May 2021. BMC Public Health. 23(1). 389–389. 6 indexed citations

Jowett, Sue, Gary A. Ford, Richard Hobbs, et al.. (2022). Cost-Effectiveness of Antihypertensive Deprescribing in Primary Care: a Markov Modelling Study Using Data From the OPTiMISE Trial. Hypertension. 79(5). 1122–1131. 7 indexed citations

Gallagher, Hugh, Jennifer Dumbleton, Tom Maishman, et al.. (2022). Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease. Trials. 23(1). 331–331. 10 indexed citations

Fisk, Helena L., Mandy Wootton, Mark Lown, et al.. (2021). Combination of the Probiotics Lacticaseibacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis, BB-12 Has Limited Effect on Biomarkers of Immunity and Inflammation in Older People Resident in Care Homes: Results From the Probiotics to Reduce Infections iN CarE home reSidentS Randomized, Controlled Trial. Frontiers in Immunology. 12. 643321–643321. 23 indexed citations

Lown, Mark, Michael E. Brown, Chloë Brown, et al.. (2020). Machine learning detection of Atrial Fibrillation using wearable technology. PLoS ONE. 15(1). e0227401–e0227401. 48 indexed citations

10.

Lown, Mark, Christopher R Wilcox, Stephanie Hughes, et al.. (2020). Patients’ views about screening for atrial fibrillation (AF): a qualitative study in primary care. BMJ Open. 10(3). e033061–e033061. 6 indexed citations

11.

Scheibl, Fiona, Carol Sinnott, James P Sheppard, et al.. (2020). GPs’ mindlines on deprescribing antihypertensives in older patients with multimorbidity: a qualitative study in English general practice. British Journal of General Practice. 71(708). e498–e507. 7 indexed citations

12.

Wilcox, Christopher R, Beth Stuart, Mark Lown, et al.. (2019). Effectiveness of the probiotic Streptococcus salivarius K12 for the treatment and/or prevention of sore throat: a systematic review. Clinical Microbiology and Infection. 25(6). 673–680. 23 indexed citations

13.

Moore, Michael, Beth Stuart, Mark Lown, et al.. (2019). Predictors of Adverse Outcomes in Uncomplicated Lower Respiratory Tract Infections. The Annals of Family Medicine. 17(3). 231–238. 10 indexed citations

14.

Lown, Mark, et al.. (2018). Influence of delayed sample processing on blood immune cell phenotypes, immune cell responses and serum anti-influenza vaccine antibody titres. Journal of Immunological Methods. 458. 8–14. 8 indexed citations

15.

Sheppard, James P, Jenni Burt, Mark Lown, et al.. (2018). OPtimising Treatment for MIld Systolic hypertension in the Elderly (OPTiMISE): protocol for a randomised controlled non-inferiority trial. BMJ Open. 8(9). e022930–e022930. 10 indexed citations

16.

Lown, Mark & David H. Peters. (2018). Industrialised medicine: a step too far?. British Journal of General Practice. 68(676). 543–544. 1 indexed citations

17.

Lown, Mark, Richard Fuller, Helen Lightowler, et al.. (2017). Mulberry-extract improves glucose tolerance and decreases insulin concentrations in normoglycaemic adults: Results of a randomised double-blind placebo-controlled study. PLoS ONE. 12(2). e0172239–e0172239. 56 indexed citations

18.

Lown, Mark, Richard Fuller, Helen Lightowler, et al.. (2015). Mulberry extract to modULate Blood glucosE Responses in noRmoglYcaemic adults (MULBERRY): study protocol for a randomised controlled trial. Trials. 16(1). 486–486. 10 indexed citations

19.

Lown, Mark, Theresa Munyombwe, Wendy J. Harrison, et al.. (2011). Association of Frontal QRS-T Angle–Age Risk Score on Admission Electrocardiogram With Mortality in Patients Admitted With an Acute Coronary Syndrome. The American Journal of Cardiology. 109(3). 307–313. 49 indexed citations

20.

Owens, Colum, et al.. (2003). Comparison of the 80-lead body surface map to physician and to 12-lead electrocardiogram in detection of acute myocardial infarction. The American Journal of Cardiology. 92(3). 252–257. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact